Value to the

Direct Investor

BIOPHARMACEUTICALS

MEDTECH & DIAGNOSTICS

Cardiovascular Devices
Prosthetic Heart Valve
Peripheral Vascular Devices
Cardiovascular Monitoring & Diagnostic Devices
Cardiovascular Surgery
Cardiac Rhythm Management
Cardiovascular Prosthetic Devices
Interventional Cardiology
Cardiac Assist Devices
Wound Care Management
Hospital Supplies
Syringes and Needles
Disposable Hospital & Surgical Supplies
Drug Delivery Devices
Inhalation Systems
Needle Free Injections
Infusion Systems
Diabetes Care Devices
Insulin Delivery & Glucose Monitoring
Ophthalmic Devices
Cataract Surgery Devices
Ophthalmic Diagnostic Equipment
Refractive Surgery Devices
ENT Devices
Hearing Implants
Diagnostic Devices
Electrosurgical Devices
Dental Equipment & Accessories
Diagnostic Imaging & MRI Systems
C/T Systems & Mammography Equipment
X-Ray & Ultrasound Systems
Nuclear Imaging Equipment
Contrast Media Injectors
Bone Densitometry
Anesthesia and Respiratory Devices
Anesthesia Machines & Disposables
Respiratory Devices & Disposables
Sleep Apnea Diagnostic Systems
Healthcare IT
Medical Imaging Information Systems
Nephrology and Urology Devices
Renal Dialysis Equipment
Orthopedic Devices
Orthobiologics & Arthroscopy
Joint Reconstruction
Trauma Fixation
Orthopedic Prosthetics
Cranium Maxillofacial Fixation (CMF)
Spinal Surgery
Endoscopy Devices & instruments
Rigid & Flexible Endoscope
In Vitro Diagnostics
Genetic Testing
Clinical Chemistry
Hematology
Immuno Chemistry
Infectious Immunology
Histology And Cytology
Patient Monitoring
Multiparameter Patient Monitoring
Micro-Electromechanical Systems
Non-invasive Blood Pressure Monitors
Neurology Devices
Neurostimulation Devices
Interventional Neurology
CSF Management
Neurosurgical Products
Radiosurgery

Diabetic Nephropathy
Diabetic Retinopathy
Hypercholesterolemia
Oral Mucositis
Gout
Acute Lymphocytic Leukemia
Bone Metastasis
Brain Cancer
Breast Cancer
Cervical Cancer
Chronic Lymphocytic Leukemia
Endometrial Cancer
Ewing Sarcoma
Gastric Cancer
Gastrointestinal Stromal Tumors
Head And Neck Cancer
Hodgkin Lymphoma
Kidney Cancer
Liver Cancer
Malignant Mesothelioma
Medullary Thyroid Cancer
Melanoma
Multiple Myeloma
Non-Hodgkin Lymphoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Testicular Cancer
Thyroid Cancer
Age Related Macular Degeneration
Keratoconjunctivitis sicca (Dry Eye)
Retinal Vein Occlusion
Acute Respiratory Distress
Syndrome
Sepsis
Staphylococcal Infections
Acute Coronary Syndrome
Angina Pectoris
Atrial Fibrillation
Coronary Artery Disease (CAD)
Critical Limb Ischemia
Hypertension
Pulmonary Arterial Hypertension
Acute Pain
Anxiety Disorders
Chronic Pain
Dementia
Diabetic Neuropathy
Obsessive-Compulsive Disorder
Osteoarthritis Pain
Parkinson's Disease
Post-Traumatic Stress Disorder
Restless Legs Syndrome
Schizophrenia
Traumatic Brain Injury
Liver Cirrhosis
Childhood Enuresis
Growth Hormone Disorders
Hyperparathyroidism
Hyperthyroidism
Guillain-Barre Syndrome
Cytomegalovirus
Fungal Infections
Gram-Negative Bacterial Infections
H1N1 Infection
Herpes Zoster
HIV-1 Infection
Human Papillomavirus Infections
Staphylococcus Aureus (MRSA)

Venture Capital

IPO / Public Markets

E ME R GIN G GR OWT H C O MPAN IE S

LEAD INVESTORS

DIRECT INVESTORS

S T R ATE GIC PARTN E R S & B U Y E R S

Healthcares Investment Marketplace

Mature

Private Equity / M&A

T R A N S F O R M I N G H E A LTH C A R E C A P ITAL M A R K E T S
on behalf of

Growth

Launch

N
D
A

Approv
al

Phase
III

Phase II

Phase I

Develop
ment

Angels / Founders

I
N
D

EXIT

SEED

Discover
y

Healthcare Development & Financing Cycle

Traditional Alternative Investment Structures

Limited Partners, Family Office,
Endowments, Foreign Trusts, Private Banks,
Sovereign Wealth
No Flexibility

2% / 20%

Venture
Capital

Private
Equity

7-year
Hold Periods

High Fees

Portfolio
Company
#1
Healthcares Investment Marketplace

10-year Fund
Cycles

Lack of Control

Growth
Equity

Lower Returns /
IRR

Hedge
Funds
Minimal
Transparency

Portfolio
Company
#2

HealthiosXchange for Direct Investors

12,000 Investors
Across (10)
Asset Classes
in (37) Countries &
2,000 Strategics in
(46) Market sectors
Seed-to-Exit
Direct/Diversified
Investment
Rules-Based
Deal Flow
Ratings &
Reviews

NO Fee
NO Carry

HIGHER RETURNS & IRR

(6,000)+
Growth
Companies
Less
Correlation

RULES-BASED
INVESTMENT STRATEGY

Proprietary
Events
Zero
Un-Invested
Capital

Messaging
&
Notifications

Reporting &
Communications

Prediction &
Sentiment Data

Real-Time
Valuations &
Research

NO
Adverse
Selection

Healthcares Investment Bank

TOTAL CONTROL

Shorter Exit
Horizons

HealthiosXchange: Higher Returns / IRR

Direct investment in the most promising healthcare companies.
Limited Partners, Family Office, Endowments,
Foreign Trusts, Private Banks, Sovereign Wealth

Venture
Capital

Growth
Equity

NO FEE NO CARRY
SHORTENED HOLD
PERIODS
GREATER LIQUIDITY

Private
Equity

Portfolio
Company
#1
Healthcares Investment Marketplace

Hedge
Funds

Portfolio
Company
#2

HealthiosXchange: Rules-Based Investing

Rules-based, direct investing in the most promising healthcare companies.
Limited Partners, Family Office, Endowments,
Foreign Trusts, Private Banks, Sovereign Wealth

1. INSTITUTIONAL
LEADERSHIP

Venture
Capital

Growth
Equity

2. STRATEGIC
VALIDATION
3. ESTABLISHED
EXIT
PATHWAY

Private
Equity

Portfolio
Company
#1
Healthcares Investment Marketplace

Hedge
Funds

Portfolio
Company
#2

HealthiosXchange: Total Control

Direct investment in the most promising healthcare companies.
Limited Partners, Family Office, Endowments,
Foreign Trusts, Private Banks, Sovereign Wealth

Total Transparency
Direct Access to Management
Influence over Valuation &
Investment Structure
100% Discretion, Flexibility
No Adverse Selection
Ultimate Diversification
Exclusive Deal Diligence
360-Degree Communication
Proprietary Event Calendar

Venture
Capital

Private
Equity

Roadshows, One-on-Ones,
Conferences

Portfolio
Company
#1
Healthcares Investment Marketplace

Portfolio
Company
#2

Growth
Equity

Hedge
Funds

HealthiosXchange for Direct Investors

12,000 Investors
Across (10)
Asset Classes
in (37) Countries &
2,000 Strategics in
(46) Market sectors
Seed-to-Exit
Direct/Diversified
Investment
Rules-Based
Deal Flow
Ratings &
Reviews

NO Fee
NO Carry

HIGHER RETURNS & IRR

(6,000)+
Growth
Companies
Less
Correlation

RULES-BASED
INVESTMENT STRATEGY

Proprietary
Events
Zero
Un-Invested
Capital

Messaging
&
Notifications

Reporting &
Communications

Prediction &
Sentiment Data

Real-Time
Valuations &
Research

NO
Adverse
Selection

Healthcares Investment Bank

TOTAL CONTROL

Shorter Exit
Horizons